Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Lixte Biotech Hlds (NQ: LIXT )

3.140 -0.120 (-3.68%)
Official Closing Price Updated: 4:29 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,500
Open 3.428
Bid (Size) 3.090 (1)
Ask (Size) 3.870 (10)
Prev. Close 3.260
Today's Range 3.140 - 3.428
52wk Range 3.000 - 5.070
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a joint underwritten public offering of 1,200,000 shares for Lixte... 
From PR Newswire
Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
From GlobeNewswire News Releases

Performance

YTD
-2.18%
-2.18%
1 Month
-24.34%
-24.34%
3 Month
-16.04%
-16.04%
6 Month
-16.04%
-16.04%
1 Year
-16.04%
-16.04%

More News

Read More
Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
From GlobeNewswire News Releases
The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatme
From GlobeNewswire News Releases
Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
From GlobeNewswire News Releases
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
From GlobeNewswire News Releases
12 Health Care Stocks Moving In Monday's Intraday Session
Tags HJLI Intraday Update EYEG
From Benzinga
WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
From Business Wire News Releases
The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 1 FDA Decision
Tags PRVL MYOV LLY
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Tags Top Gainers Benzinga Markets
From Benzinga
The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 1 FDA Decision
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.